References: 1. Urocit-K [package insert]. San Antonio, TX: Mission Pharmacal Company; 2009. 2. Pak CYC, Fuller C, Sakhaee K, et al. Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol. 1985;134(1):11-19. 3. Preminger GM, Sakhaee K, Skurla C, et al. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 1985;134(1):20-23. 4. Pak CYC, Peterson R, Sakhaee K, et al. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. Am J Med. 1985;79(3):284-288. 5. Lipkin ME, Preminger GM. Demystifying the medical management of nephrolithiasis. Rev Urol. 2011;13(1):34-38.. Urocit-K, available in 3 dosage strengths, is a prescription treatment that restores the chemicals in the kidneys that help prevent kidney stones. It reduces the formation of several common types of kidney stones, including calcium oxalate and uric acid stones. The highest strength, Urocit-K 15 mEq, is designed to minimize the number of tablets you may need to take each day. In clinical .